Do Mutations Turn p53 into an Oncogene?
Open Access
- 11 December 2019
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (24), 6241
- https://doi.org/10.3390/ijms20246241
Abstract
The key role of p53 as a tumor suppressor became clear when it was realized that this gene is mutated in 50% of human sporadic cancers, and germline mutations expose carriers to cancer risk throughout their lifespan. Mutations in this gene not only abolish the tumor suppressive functions of p53, but also equip the protein with new pro-oncogenic functions. Here, we review the mechanisms by which these new functions gained by p53 mutants promote tumorigenesis.This publication has 144 references indexed in Scilit:
- Evolution and dynamics of pancreatic cancer progressionOncogene, 2013
- Allele-Specific p53 Mutant ReactivationCancer Cell, 2012
- Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate PathwayCell, 2012
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axisCell Death & Differentiation, 2011
- Genetically transforming human mesenchymal stem cells to sarcomasCancer, 2009
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997